7.1.2021 20:44:53 CET | Monsenso |
Ændring i ledelse/godkendte rådgivere
Monsenso offentliggør i dag, på vegne af bestyrelsen, forslaget om at vælge Peter Høngaard Andersen og Jacob Hahn Michelsen som nye bestyrelsesmedlemmer på den ekstraordinære generalforsamling sat til d. 29. januar 2021. Indkaldelse til mødet udsendes separat.
Selskabsmeddelelse nr. 1-2021
København den 7. jan. 2021
Monsenso – førende udbyder af mobile sundhedsløsninger til mental sundhed – planlægger at styrke bestyrelsen ved indstilling af to nye professionelle bestyrelsesmedlemmer til at støtte Monsenso i selskabets videre vækstrejse; Peter Høngaard Andersen, tidligere administrerende direktør i Innovationsfonden og VP i Lundbeck; Jacob Hahn Michelsen, SVP Private & Public i NNIT A/S.
Det nuværende bestyrelsesmedlem, Thomas Knudsen, har tilbudt at træde ud af bestyrelsen på den ekstraordinære generalforsamling. Thomas har i flere år støttet Monsenso’s vækst fra at være et forskningsprojekt til at blive et internationalt børsnoteret selskab på Nasdaq First North Growth Market Copenhagen.
Bestyrelsen og ledelsen i Monsenso vil gerne takke Thomas Knudsen for hans fremragende arbejde. Hans bidrag har været afgørende for opbygningen af produktporteføljen og sikring af de første kapitalrejsninger, samt for at støtte direktionen og endelig børsnoteringen af virksomheden.
Den nye bestyrelse planlægger at konstituere sig med Jukka Pertola som formand og Jakob Bardram som næstformand indtil næste årlige generalforsamling d. 14. april 2021, hvor Jukka Pertola forventes at træde tilbage som formand.
Med nominering af de nye bestyrelsesmedlemmer på dette tidspunkt sikrer selskabet en god introduktion og overdragelse af ansvarsområder i perioden frem til generalforsamlingen.
Jukka Pertola kommenterede: ”Siden jeg blev professionelt bestyrelsesmedlem, har jeg været heldig at blive inviteret til flere bestyrelser i spændende virksomheder, hvoraf den ene er Monsenso. For at imødekomme kravene til god selskabsledelse, har jeg dog besluttet at reducere mit antal af bestyrelsesposter og formandskaber. Vi har fundet et par usædvanligt stærke nye bestyrelsesmedlemmer, der kan bidrage til at bringe Monsenso til det næste niveau. Jacob Hahn Michelsen har omfattende erfaring inden for farmaceutisk- og sundhedsrelateret software og it, det regulatoriske område for medicinske applikationer og en værdifuld knowhow inden for branchen, mens Peter Høngaard Andersen har betydelig erfaring indenfor videnskab og forskning, lægemidler, neurologi, IP-rettigheder, samt innovation og finansiering.”
Forespørgsler vedrørende denne meddelelse skal rettes til:
Monsenso:
Chairman of the boardJukka P. PertolaTel. +45 20 19 82 20E-mail: jukka.pertola@pertola.com
CEO Thomas LethenborgTlf. +45 21 29 88 27E-mail: lethenborg@monsenso.com
Certified Adviser:
Norden CEF ApSJohn NordenTlf. +45 20 72 02 00E-mail: jn@nordencef.dk
Om Monsenso
Monsenso er en innovativ virksomhed, som tilbyder en mobil sundheds-it løsning. Vores mission er at bidrage til bedre mental sundhed til flere personer og lavere omkostninger. Vores løsning bidrager til optimering af behandlingen for psykiske lidelser og giver et detaljeret overblik over patienters mentale sundhed via indsamling af data om mental tilstand, adhærens og adfærd. Løsningen forbinder patienter, omsorgspersoner og behandlere for at muliggøre en personligt tilpasset behandling, distancebehandling samt tidlig opsporing og intervention. Baseret på vedvarende forskning og udvikling er vores team opsat på at udvikle løsninger, der passer ind i brugernes liv, øger patienters livskvalitet og forbedrer effekten af behandlingen. Få mere at vide på www.monsenso.com
Vedhæftninger
Download selskabsmeddelelse.pdf
7.1.2021 20:44:53 CET | Monsenso |
Chang. board/management/certified advisors
Monsenso today announces that the board of Directors has decided to call for an Extraordinary General Meeting on January 29th, 2021, where two new members are proposed to be elected for the board. Notice to attend the meeting will be issued separately.
Company Announcement no. 1-2021
Copenhagen, 2021.01.07
Monsenso – a leading provider of mobile health solutions for mental health – plans to further strengthen the board by nominating two new professional board members with strong qualifications and competencies to support Monsenso in getting to the next level in the company’s growth journey: Peter Høngaard Andersen, formerly. Managing Director at Innovation Fund Denmark and VP at Lundbeck; Jacob Hahn Michelsen, SVP Private & Public at NNIT A/S.
Current board member Thomas Knudsen has offered to resign from his position on the board at the Extraordinary General Meeting. Thomas has supported Monsenso’s growth for several years from being a university research project spin-out to becoming an international publicly listed company on Nasdaq First North Growth Market Copenhagen. The board and the management of Monsenso would like to thank Thomas Knudsen for his outstanding work. His contributions have been essential in building up the product portfolio, securing the first rounds of financing, supporting the management and finally listing the company.
The new board is planning to constitute itself with Jukka Pertola as the Chairman and Jakob Bardram as the Vice Chairman until the next ordinary Annual General Meeting on April 14, 2021 where Jukka Pertola is expected to resign as the Chairman. Nomination of the new board members in January will help ensure an appropriate introduction, as well as a smooth transition and handover of responsibilities in the period leading up to the Annual General Meeting.
Jukka Pertola commented: ”Since I became a professional board member, I have been lucky to be invited to multiple boards of exciting companies, one of them being Monsenso. However, to address the good corporate governance requirements, I have decided to reduce my number of board positions and chairmanships. We have found an exceptionally strong pair of new board members, who can contribute to bringing Monsenso to the next level. Jacob Hahn Michelsen has extensive experience in pharma- and health-related software and IT, regulatory environment of medical applications and a valuable industry knowhow, while Peter Høngaard brings considerable experience from science and research, pharmaceuticals, neurology, intellectual property rights, innovation and funding.“
Any inquiries regarding this notice should be directed to:
Monsenso:
Chairman of the boardJukka P. PertolaTel. +45 20 19 82 20E-mail: jukka.pertola@pertola.com
CEO Thomas LethenborgTel. +45 21 29 88 27E-mail: lethenborg@monsenso.com
Certified Adviser:
Norden CEF ApSJohn NordenTel. +45 20 72 02 00E-mail: jn@nordencef.dk
About Monsenso
Monsenso is an innovative technology company offering a mobile Health (mHealth) solution. Our mission is to help provide better mental health to more people at lower costs. Our solution helps optimise the treatment of mental disorders and gives a detailed overview of an individual’s mental health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. Based on continuous research and development, our team is committed to developing solutions that fit seamlessly into the lives of individuals, increase their quality of life and improve the efficacy of mental health treatment. To learn more visit www.monsenso.com
Attachments
Download announcement as PDF.pdf
